3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
18
Breast Neoplasms
16
Lung Neoplasms
10
Carcinoma, Non-Small-Cell Lung
6
Prostatic Neoplasms
5
Melanoma
5
Colorectal Neoplasms
5
Brain Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Myeloproliferative Disorders
3
Leukemia, Myeloid, Acute
3
Kidney Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Hepatocellular
3
Recurrence
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Lung Diseases
2
Glioma
2
Glioblastoma
2
Genetic Predisposition to Disease
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Interventions
rozanolixizumab
5
ravulizumab
5
zilucoplan
4
fludarabine
3
Cyclophosphamide
3
telitacicept
2
inebilizumab
2
talquetamab
1
remibrutinib
1
iptacopan
1
efgartigimod alfa
1
Therapeutics
1
Prednisone
1
Prednisolone
1
Plasma Exchange
1
Immunoglobulins, Intravenous
1
HBM9161
1
Cladribine
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myasthenia Gravis
×
Blood Specimen Collection
×
90 days
×
Clear all
NCT00704626
2026-05-18
SAA
University of California, Davis
Enrolling by invitation
120 enrolled